Macrophage polarization at the crossroad between hiv-1 infection and cancer development

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 33, Issue 6, 2013, Pages 1145-1152

  Alfano, Massimo ^a   Graziano, Francesca ^a,b   Genovese, Luca ^a,b   Poli, Guido ^a,b  

^a AIDS Immunopathogenesis Unit   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Cancer; HIV; Human cytomegalovirus; Human herpes virus 8; M1; M2

Indexed keywords

G PROTEIN COUPLED RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 3; INTERLEUKIN 4; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CANCER PATIENT; CARCINOGENESIS; HERPES VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; MACROPHAGE; MACROPHAGE FUNCTION; MONOCYTE; MONONUCLEAR PHAGOCYTE; NONHUMAN; PHAGOCYTE; POLARIZATION; PRIORITY JOURNAL; TUMOR IMMUNITY;

CANCER; HIV; HUMAN CYTOMEGALOVIRUS; HUMAN HERPES VIRUS 8; M1; M2; MACROPHAGE; POLARIZATION;

ADAPTIVE IMMUNITY; ANIMALS; CELL POLARITY; DISEASE PROGRESSION; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, INNATE; MACROPHAGE ACTIVATION; MACROPHAGES; MICE; NEOPLASMS; PHENOTYPE; SENSITIVITY AND SPECIFICITY;

EID: 84879105849     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.112.300171     Document Type: Article

References (96)

1. Collman RG, Perno CF, Crowe SM, Stevenson M, Montaner LJ. HIV and cells of macrophage/dendritic lineage and other non-T cell reservoirs: new answers yield new questions. J Leukoc Biol. 2003;74:631-634.
2. Gendelman HE, Orenstein JM, Baca LM, Weiser B, Burger H, Kalter DC, Meltzer MS. The macrophage in the persistence and pathogenesis of HIV infection. AIDS. 1989;3:475-495.
3. Gray F, Bélec L, Chrétien F, Dubreuil-Lemaire ML, Ricolfi F, Wingertsmann L, Poron F, Gherardi R. Acute, relapsing brain oedema with diffuse blood-brain barrier alteration and axonal damage in the acquired immunodeficiency syndrome. Neuropathol Appl Neurobiol. 1998;24:209-216.
4. Mann DL, Gartner S, Le Sane F, Buchow H, Popovic M. HIV-1 transmission and function of virus-infected monocytes/macrophages. J Immunol. 1990;144:2152-2158.
5. Stevenson M, Gendelman HE. Cellular and viral determinants that regulate HIV-1 infection in macrophages. J Leukoc Biol. 1994;56:278-288.
6. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004;25:677-686.
7. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-Associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23:549-555.
8. Goerdt S, Politz O, Schledzewski K, Birk R, Gratchev A, Guillot P, Hakiy N, Klemke CD, Dippel E, Kodelja V, Orfanos CE. Alternative versus classical activation of macrophages. Pathobiology. 1999;67:222-226.
9. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest. 2012;122:787-795.
10. Abramson SL, Gallin JI. IL-4 inhibits superoxide production by human mononuclear phagocytes. J Immunol. 1990;144:625-630.
11. Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Front Biosci. 2008;13:453-461.
12. Guénet JL. The mouse genome. Genome Res. 2005;15:1729-1740.
13. Taylor PR, Martinez-Pomares L, Stacey M, Lin HH, Brown GD, Gordon S. Macrophage receptors and immune recognition. Annu Rev Immunol. 2005;23:901-944.
14. Cassol E, Cassetta L, Rizzi C, Alfano M, Poli G. M1 and M2a polarization of human monocyte-derived macrophages inhibits HIV-1 replication by distinct mechanisms. J Immunol. 2009;182:6237-6246.
15. Cassol E, Cassetta L, Alfano M, Poli G. Macrophage polarization and HIV-1 infection. J Leukoc Biol. 2010;87:599-608.
16. Ricardo SD, van Goor H, Eddy AA. Macrophage diversity in renal injury and repair. J Clin Invest. 2008;118:3522-3530.
17. Quiding-Järbrink M, Raghavan S, Sundquist M. Enhanced M1 macrophage polarization in human helicobacter pylori-Associated atrophic gastritis and in vaccinated mice. PLoS One. 2010;5:-e15018.
18. Edin S, Wikberg ML, Dahlin AM, Rutegård J, Öberg Å, Oldenborg PA, Palmqvist R. The distribution of macrophages with a M1 or M2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer. PLoS One. 2012;7:-e47045.
19. Schmieder A, Michel J, Schönhaar K, Goerdt S, Schledzewski K. Differentiation and gene expression profile of tumor-Associated macrophages. Semin Cancer Biol. 2012;22:289-297.
20. Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol. 2009;27:451-483.
21. Cassol E, Cassetta L, Rizzi C, Gabuzda D, Alfano M, Poli G. Dendritic cell-specific icam-3 grabbing nonintegrin mediates hiv-1 infection of and transmission by m2a-polarized macrophages in vitro. Aids. 2012
22. Kuroda E, Yoshida Y, En Shan B, Yamashita U. Suppression of macrophage interleukin-12 and tumour necrosis factor-Alpha production in mice infected with Toxocara canis. Parasite Immunol. 2001;23:305-311.
23. Mantovani A, Schioppa T, Porta C, Allavena P, Sica A. Role of tumorassociated macrophages in tumor progression and invasion. Cancer Metastasis Rev. 2006;25:315-322.
24. Bhatia K, Shiels MS, Berg A, Engels EA. Sarcomas other than Kaposi sarcoma occurring in immunodeficiency: interpretations from a systematic literature review. Curr Opin Oncol. 2012;24:537-546.
25. Kwakkenbos MJ, Kop EN, Stacey M, Matmati M, Gordon S, Lin HH, Hamann J. The EGF-TM7 family: a postgenomic view. Immunogenetics. 2004;55:655-666.
26. Kwakkenbos MJ, Matmati M, Madsen O, Pouwels W, Wang Y, Bontrop RE, Heidt PJ, Hoek RM, Hamann J. An unusual mode of concerted evolution of the EGF-TM7 receptor chimera EMR2. FASEB J. 2006;20:2582-2584.
27. Heusinkveld M, van der Burg SH. Identification and manipulation of tumor associated macrophages in human cancers. J Transl Med. 2011;9:216.
28. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009;9:239-252.
29. Lin H-H, Gordon S. Macrophage phenotype in tumours. In: Lawrence L, Hagemann T, editors.Tumor-Associated Macrophages. New York, NY: Springer Science. 2012:3-16.
30. Austyn JM, Gordon S. F4/80, a monoclonal antibody directed specifically against the mouse macrophage. Eur J Immunol. 1981;11:805-815.
31. Lin HH, Faunce DE, Stacey M, Terajewicz A, Nakamura T, Zhang-Hoover J, Kerley M, Mucenski ML, Gordon S, Stein-Streilein J. The macrophage F4/80 receptor is required for the induction of antigen-specific efferent regulatory T cells in peripheral tolerance. J Exp Med. 2005;201:1615-1625.
32. van den Berg TK, Kraal G. A function for the macrophage F4/80 molecule in tolerance induction. Trends Immunol. 2005;26:506-509.
33. McKnight AJ, Gordon S. EGF-TM7: a novel subfamily of seven-transmembrane- region leukocyte cell-surface molecules. Immunol Today. 1996;17:283-287.
34. Bjarnadóttir TK, Fredriksson R, Schiöth HB. The adhesion GPCRs: a unique family of G protein-coupled receptors with important roles in both central and peripheral tissues. Cell Mol Life Sci. 2007;64:2104-2119.
35. Chang NC, Hung SI, Hwa KY, Kato I, Chen JE, Liu CH, Chang AC. A macrophage protein, Ym1, transiently expressed during inflammation is a novel mammalian lectin. J Biol Chem. 2001;276:17497-17506.
36. Raes G, De Baetselier P, Noël W, Beschin A, Brombacher F, Hassanzadeh Gh G. Differential expression of FIZZ1 and Ym1 in alternatively versus classically activated macrophages. J Leukoc Biol. 2002;71:597-602.
37. Jarvis MA, Nelson JA. Molecular basis of persistence and latency. In: Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R, Yamanishi K, editors. Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis. Cambridge: Cambridge University Press; 2007.
38. Sinclair J, Sissons P. Latent and persistent infections of monocytes and macrophages. Intervirology. 1996;39:293-301.
39. Sinzger C, Jahn G. Human cytomegalovirus cell tropism and pathogenesis. Intervirology. 1996;39:302-319.
40. Jiménez VC, Booiman T, de Taeye SW, van Dort KA, Rits MA, Hamann J, Kootstra NA. Differential expression of HIV-1 interfering factors in monocyte-derived macrophages stimulated with polarizing cytokines or interferons. Sci Rep. 2012;2:763.
41. Booss J, Dann PR, Griffith BP, Kim JH. Host defense response to cytomegalovirus in the central nervous system. Predominance of the monocyte. Am J Pathol. 1989;134:71-78.
42. Pulliam L. Cytomegalovirus preferentially infects a monocyte derived macrophage/microglial cell in human brain cultures: neuropathology differs between strains. J Neuropathol Exp Neurol. 1991;50:432-440.
43. Degré M. Has cytomegalovirus infection any role in the development of atherosclerosis? Clin Microbiol Infect. 2002;8:191-195.
44. Streblow DN, Orloff SL, Nelson JA. Do pathogens accelerate atherosclerosis? J Nutr. 2001;131:2798S-2804S.
45. Smith MS, Bentz GL, Alexander JS, Yurochko AD. Human cytomegalovirus induces monocyte differentiation and migration as a strategy for dissemination and persistence. J Virol. 2004;78:4444-4453.
46. Smith MS, Bentz GL, Smith PM, Bivins ER, Yurochko AD. HCMV activates PI(3)K in monocytes and promotes monocyte motility and transendothelial migration in a PI(3)K-dependent manner. J Leukoc Biol. 2004;76:65-76.
47. Yurochko AD, Huang ES. Human cytomegalovirus binding to human monocytes induces immunoregulatory gene expression. J Immunol. 1999;162:4806-4816.
48. Chan G, Bivins-Smith ER, Smith MS, Smith PM, Yurochko AD. Transcriptome analysis reveals human cytomegalovirus reprograms monocyte differentiation toward an M1 macrophage. J Immunol. 2008;181: 698-711.
49. Cornelissen M, van der Kuyl AC, van den Burg R, Zorgdrager F, van Noesel CJ, Goudsmit J. Gene expression profile of AIDS-related Kaposi's sarcoma. BMC Cancer. 2003;3:7.
50. Monini P, Colombini S, Stürzl M, et al. Reactivation and persistence of human herpesvirus-8 infection in B cells and monocytes by Th-1 cytokines increased in Kaposi's sarcoma. Blood. 1999;93:4044-4058.
51. Ensoli B, Sgadari C, Barillari G, Sirianni MC, Stürzl M, Monini P. Biology of Kaposi's sarcoma. Eur J Cancer. 2001;37:1251-1269.
52. Deeks SG, Autran B, Berkhout B, et al. Towards an hiv cure: a global scientific strategy. Nat Rev Immunol. 2012;12:607-614
53. Orenstein JM. Replication of HIV-1 in vivo and in vitro. Ultrastruct Pathol. 2007;31:151-167.
54. Carter CA, Ehrlich LS. Cell biology of HIV-1 infection of macrophages. Annu Rev Microbiol. 2008;62:425-443.
55. Morrow G, Vachot L, Vagenas P, Robbiani M. Current concepts of HIV transmission. Curr HIV/AIDS Rep. 2007;4:29-35.
56. Wahl SM, Greenwell-Wild T, Vázquez N. HIV accomplices and adversaries in macrophage infection. J Leukoc Biol. 2006;80:973-983.
57. Ziegler-Heitbrock L. The CD14+ CD16+ blood monocytes: their role in infection and inflammation. J Leukoc Biol. 2007;81:584-592.
58. Jaworowski A, Kamwendo DD, Ellery P, Sonza S, Mwapasa V, Tadesse E, Molyneux ME, Rogerson SJ, Meshnick SR, Crowe SM. CD16+ monocyte subset preferentially harbors HIV-1 and is expanded in pregnant Malawian women with Plasmodium falciparum malaria and HIV-1 infection. J Infect Dis. 2007;196:38-42.
59. Williams DW, Eugenin EA, Calderon TM, Berman JW. Monocyte maturation, HIV susceptibility, and transmigration across the blood brain barrier are critical in HIV neuropathogenesis. J Leukoc Biol. 2012;91:401-415.
60. Brown JN, Kohler JJ, Coberley CR, Sleasman JW, Goodenow MM. HIV-1 activates macrophages independent of Toll-like receptors. PLoS One. 2008;3:-e3664.
61. Porcheray F, Samah B, Léone C, Dereuddre-Bosquet N, Gras G. Macrophage activation and human immunodeficiency virus infection: HIV replication directs macrophages towards a pro-inflammatory phenotype while previous activation modulates macrophage susceptibility to infection and viral production. Virology. 2006;349:112-120.
62. Graff JW, Dickson AM, Clay G, McCaffrey AP, Wilson ME. Identifying functional microRNAs in macrophages with polarized phenotypes. J Biol Chem. 2012;287:21816-21825.
63. Martinez-Nunez RT, Louafi F, Friedmann PS, Sanchez-Elsner T. MicroRNA-155 modulates the pathogen binding ability of dendritic cells (DCs) by down-regulation of DC-specific intercellular adhesion molecule-3 grabbing non-integrin (DC-SIGN). J Biol Chem. 2009;284:16334-16342.
64. Swaminathan G, Rossi F, Sierra LJ, Gupta A, Navas-Martín S, Martín-García J. A role for microRNA-155 modulation in the anti-HIV-1 effects of Tolllike receptor 3 stimulation in macrophages. PLoS Pathog. 2012;8:-e1002937.
65. van der Vlist M, van der Aar AM, Gringhuis SI, Geijtenbeek TB. Innate signaling in HIV-1 infection of dendritic cells. Curr Opin HIV AIDS. 2011;6:348-352.
66. Gobeil LA, Lodge R, Tremblay MJ. Differential HIV-1 endocytosis and susceptibility to virus infection in human macrophages correlate with cell activation status. J Virol. 2012;86:10399-10407.
67. Herbein G, Varin A. The macrophage in HIV-1 infection: from activation to deactivation? Retrovirology. 2010;7:33.
68. Khallou-Laschet J, Varthaman A, Fornasa G, Compain C, Gaston AT, Clement M, Dussiot M, Levillain O, Graff-Dubois S, Nicoletti A, Caligiuri G. Macrophage plasticity in experimental atherosclerosis. PLoS One. 2010;5:-e8852.
69. Zanni MV, Grinspoon SK. HIV-specific immune dysregulation and atherosclerosis. Curr HIV/AIDS Rep. 2012;9:200-205.
70. Stöger JL, Goossens P, de Winther MP. Macrophage heterogeneity: relevance and functional implications in atherosclerosis. Curr Vasc Pharmacol. 2010;8:233-248.
71. Stöger JL, Gijbels MJ, van der Velden S, Manca M, van der Loos CM, Biessen EA, Daemen MJ, Lutgens E, de Winther MP. Distribution of macrophage polarization markers in human atherosclerosis. Atherosclerosis. 2012;225:461-468.
72. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell. 2010;141:39-51.
73. Ruffell B, DeNardo DG, Affara NI, Coussens LM. Lymphocytes in cancer development: polarization towards pro-tumor immunity. Cytokine Growth Factor Rev. 2010;21:3-10.
74. Dumont P, Berton A, Nagy N, Sandras F, Tinton S, Demetter P, Mascart F, Allaoui A, Decaestecker C, Salmon I. Expression of galectin-3 in the tumor immune response in colon cancer. Lab Invest. 2008;88:896-906.
75. Khorana AA, Ryan CK, Cox C, Eberly S, Sahasrabudhe DM. Vascular endothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with Stage II and Stage III colon carcinoma: a role for the host response in prognosis. Cancer. 2003;97:960-968.
76. Oberg A, Samii S, Stenling R, Lindmark G. Different occurrence of CD8+, CD45R0+, and CD68+ immune cells in regional lymph node metastases from colorectal cancer as potential prognostic predictors. Int J Colorectal Dis. 2002;17:25-29.
77. Zhou Q, Peng RQ, Wu XJ, Xia Q, Hou JH, Ding Y, Zhou QM, Zhang X, Pang ZZ, Wan DS, Zeng YX, Zhang XS. The density of macrophages in the invasive front is inversely correlated to liver metastasis in colon cancer. J Transl Med. 2010;8:13.
78. Funada Y, Noguchi T, Kikuchi R, Takeno S, Uchida Y, Gabbert HE. Prognostic significance of CD8+ T cell and macrophage peritumoral infiltration in colorectal cancer. Oncol Rep. 2003;10:309-313.
79. Kang JC, Chen JS, Lee CH, Chang JJ, Shieh YS. Intratumoral macrophage counts correlate with tumor progression in colorectal cancer. J Surg Oncol. 2010;102:242-248.
80. Pancione M, Forte N, Sabatino L, Tomaselli E, Parente D, Febbraro A, Colantuoni V. Reduced beta-catenin and peroxisome proliferator-Activated receptor-gamma expression levels are associated with colorectal cancer metastatic progression: correlation with tumor-Associated macrophages, cyclooxygenase 2, and patient outcome. Hum Pathol. 2009;40:714-725.
81. Sica A, Larghi P, Mancino A, Rubino L, Porta C, Totaro MG, Rimoldi M, Biswas SK, Allavena P, Mantovani A. Macrophage polarization in tumour progression. Semin Cancer Biol. 2008;18:349-355.
82. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell. 2006;124:263-266.
83. Biswas SK, Gangi L, Paul S, Schioppa T, Saccani A, Sironi M, Bottazzi B, Doni A, Vincenzo B, Pasqualini F, Vago L, Nebuloni M, Mantovani A, Sica A. A distinct and unique transcriptional program expressed by tumorassociated macrophages (defective NF-kappaB and enhanced IRF-3/STAT1 activation). Blood. 2006;107:2112-2122.
84. Sakai Y, Honda M, Fujinaga H, Tatsumi I, Mizukoshi E, Nakamoto Y, Kaneko S. Common transcriptional signature of tumor-infiltrating mononuclear inflammatory cells and peripheral blood mononuclear cells in hepatocellular carcinoma patients. Cancer Res. 2008;68:10267-10279.
85. Beck AH, Espinosa I, Edris B, Li R, Montgomery K, Zhu S, Varma S, Marinelli RJ, van de Rijn M, West RB. The macrophage colony-stimulating factor 1 response signature in breast carcinoma. Clin Cancer Res. 2009;15:778-787.
86. Sica A, Saccani A, Mantovani A. Tumor-Associated macrophages: a molecular perspective. Int Immunopharmacol. 2002;2:1045-1054.
87. Coussens LM, Tinkle CL, Hanahan D, Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell. 2000;103:481-490.
88. Baay M, Brouwer A, Pauwels P, Peeters M, Lardon F. Tumor cells and tumor-Associated macrophages: secreted proteins as potential targets for therapy. Clin Dev Immunol. 2011;2011:565187.
89. Duluc D, Corvaisier M, Blanchard S, Catala L, Descamps P, Gamelin E, Ponsoda S, Delneste Y, Hebbar M, Jeannin P. Interferon-gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-Associated macrophages. Int J Cancer. 2009;125:367-373.
90. Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, Huhn RD, Song W, Li D, Sharp LL, Torigian DA, O'Dwyer PJ, Vonderheide RH. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 2011;331:1612-1616.
91. Coscia M, Quaglino E, Iezzi M, Curcio C, Pantaleoni F, Riganti C, Holen I, Mönkkönen H, Boccadoro M, Forni G, Musiani P, Bosia A, Cavallo F, Massaia M. Zoledronic acid repolarizes tumour-Associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med. 2010;14:2803-2815.
92. Huang Z, Zhang Z, Jiang Y, Zhang D, Chen J, Dong L, Zhang J. Targeted delivery of oligonucleotides into tumor-Associated macrophages for cancer immunotherapy. J Control Release. 2012;158:286-292.
93. Rolny C, Mazzone M, Tugues S, et al. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell. 2011;19:31-44.
94. Germano G, Frapolli R, Simone M, et al. Antitumor and anti-inflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res. 2010;70:2235-2244.
95. Fujita E, Shimizu A, Masuda Y, Kuwahara N, Arai T, Nagasaka S, Aki K, Mii A, Natori Y, Iino Y, Katayama Y, Fukuda Y. Statin attenuates experimental anti-glomerular basement membrane glomerulonephritis together with the augmentation of alternatively activated macrophages. Am J Pathol. 2010;177:1143-1154.
96. Cassetta L, Cassol E, Poli G. Macrophage polarization in health and disease. ScientificWorldJournal. 2011;11:2391-2402.